P2RX7 and skin basal cell carcinoma: Indeed, the recent report of the well-tolerated BIL010t, topical anti-P2X7 treatment of BCC (Biosceptre) revealed promising patient outcomes with 65% of patients treated showing reduced lesion area and 20% with stable disease (Gilbert et al., 2017).